Login Register Cart 0
Review Article

抗炎药物预防心房颤动复发的疗效观察

卷 28, 期 1, 2021

发表于: 02 March, 2020

页: [137 - 151] 页: 15

弟呕挨: 10.2174/1389450121666200302095103

价格: $65

摘要

一些研究表明炎症和房颤(AF)复发之间存在联系，特别是消融后，这是一种导致局部炎症的治疗选择。另一方面，一般来说，每个心房颤动都可能导致另一个心房颤动。因此，防止房颤复发对患者的预后非常重要。本文就具有抗炎作用的药物在预防房颤复发中的作用进行综述。有几个随机对照试验(rct)和荟萃分析使用具有抗炎作用的药物预防房颤复发，这些药物包括类固醇、秋水仙碱、他汀类药物和n-3脂肪酸(n-3 FA)。评估抗炎药物预防AF复发的临床试验导致皮质激素、他汀类药物和n-3 FAs的结果不一致。这些结果可能与这一事实有关炎症不是唯一因素负责引发房颤复发。例如,结构,机电改造最重要的因素可能引发房颤的复发,但这些因素未得到大部分的研究报道。因此，需要进一步的临床试验来比较抗炎药物对有无其他因素的AF患者的疗效。秋水仙碱是一种强效抗炎药物，目前的研究有限。然而，所有关于秋水仙碱用于房颤的研究都是一致且有希望的，特别是在阵发性房颤患者消融后短期使用秋水仙碱的情况下。因此，秋水仙碱可能是进一步临床研究复发性房颤的一个有希望的候选药物。

关键词: 心房颤动，房颤复发，炎症，消融，电转复，结构重构，心律失常，CRP

« Previous Next »
[1]
Henningsen, K.M.; Nilsson, B.; Bruunsgaard, H.; Chen, X.; Pedersen, B.K.; Svendsen, J.H. Prognostic impact of hs- CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation Scand. Cardiovasc. J., 2009, 43(5), 285-291.
[http://dx.doi.org/10.1080/14017430802653676] [PMID: 19117239]
[2]
Henningsen, K.M.; Therkelsen, S.K.; Bruunsgaard, H.; Krabbe, K.S.; Pedersen, B.K.; Svendsen, J.H. Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand. J. Clin. Lab. Invest., 2009, 69(3), 425-432.
[http://dx.doi.org/10.1080/00365510802676848] [PMID: 19204850]
[3]
Letsas, K.P.; Weber, R.; Burkle, G.; Mihas, C.C.; Minners, J.; Kalusche, D.; Arentz, P. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace, 2009, 11(2), 158-163.
[http://dx.doi.org/10.1093/europace/eun309] [PMID: 19010799]
[4]
Rizos, I.; Rigopoulos, A.G.; Kalogeropoulos, A.S.; Tsiodras, S.; Dragomanovits, S.; Sakadakis, E.A.; Faviou, E.; Kremastinos, D.T. Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence. J. Hum. Hypertens., 2010, 24(7), 447-457.
[http://dx.doi.org/10.1038/jhh.2009.89] [PMID: 20072146]
[5]
Barassi, A.; Pezzilli, R.; Morselli-Labate, A.M.; Lombardi, F.; Belletti, S.; Dogliotti, G.; Corsi, M.M.; Merlini, G.; Melzi d’Eril, G.V. Serum amyloid a and C-reactive protein independently predict the recurrences of atrial fibrillation after cardioversion in patients with preserved left ventricular function. Can. J. Cardiol., 2012, 28(5), 537-541.
[http://dx.doi.org/10.1016/j.cjca.2012.02.014] [PMID: 22552174]
[6]
Smit, MD; Maass, AH; De Jong, AM; Muller Kobold, AC; Van Veldhuisen, DJ; Van Gelder, IC Role of inflammation in early atrial fibrillation recurrence, 2012.
[http://dx.doi.org/10.1093/europace/eur402] [PMID: 22237586]
[7]
Kimura, T.; Takatsuki, S.; Inagawa, K.; Katsumata, Y.; Nishiyama, T.; Nishiyama, N.; Fukumoto, K.; Aizawa, Y.; Tanimoto, Y.; Tanimoto, K.; Fukuda, K. Serum inflammation markers predicting successful initial catheter ablation for atrial fibrillation. Heart Lung Circ., 2014, 23(7), 636-643.
[http://dx.doi.org/10.1016/j.hlc.2014.02.003] [PMID: 24613042]
[8]
Liu, T.; Li, G.; Li, L.; Korantzopoulos, P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J. Am. Coll. Cardiol., 2007, 49(15), 1642-1648.
[http://dx.doi.org/10.1016/j.jacc.2006.12.042] [PMID: 17433956]
[9]
Wu, N.; Xu, B.; Xiang, Y.; Wu, L.; Zhang, Y.; Ma, X.; Tong, S.; Shu, M.; Song, Z.; Li, Y.; Zhong, L. Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis. Int. J. Cardiol., 2013, 169(1), 62-72.
[http://dx.doi.org/10.1016/j.ijcard.2013.08.078] [PMID: 24095158]
[10]
Leftheriotis, D.I.; Fountoulaki, K.T.; Flevari, P.G.; Parissis, J.T.; Panou, F.K.; Andreadou, I.T.; Venetsanou, K.S.; Iliodromitis, E.K.; Kremastinos, D.T. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int. J. Cardiol., 2009, 135(3), 361-369.
[http://dx.doi.org/10.1016/j.ijcard.2008.04.012] [PMID: 18640731]
[11]
Liu, J.; Fang, P.H.; Dibs, S.; Hou, Y.; Li, X.F.; Zhang, S. High-sensitivity C-reactive protein as a predictor of atrial fibrillation recurrence after primary circumferential pulmonary vein isolation. Pacing Clin. Electrophysiol., 2011, 34(4), 398-406.
[http://dx.doi.org/10.1111/j.1540-8159.2010.02978.x] [PMID: 21091744]
[12]
Lappegård, K.T.; Hovland, A.; Pop, G.A. Mollnes, T.E. Atrial fibrillation: inflammation in disguise? Scand. J. Immunol., 2013, 78(2), 112-119.
[http://dx.doi.org/10.1111/sji.12061] [PMID: 23672430]
[13]
Hu, Y.F.; Chen, Y.J.; Lin, Y.J.; Chen, S.A. Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol., 2015, 12(4), 230-243.
[http://dx.doi.org/10.1038/nrcardio.2015.2] [PMID: 25622848]
[14]
Casanova, P.; Artola, R.T.; Mihos, C.G.; Pineda, A.M.; Santana, O. The cardiovascular effects of colchicine: a comprehensive review. Cardiol. Rev., 2015, 23(6), 317-322.
[http://dx.doi.org/10.1097/CRD.0000000000000056] [PMID: 25688661]
[15]
Deftereos, S.; Giannopoulos, G.; Papoutsidakis, N.; Panagopoulou, V.; Kossyvakis, C.; Raisakis, K.; Cleman, M.W.; Stefanadis, C. Colchicine and the heart: pushing the envelope. J. Am. Coll. Cardiol., 2013, 62(20), 1817-1825.
[http://dx.doi.org/10.1016/j.jacc.2013.08.726] [PMID: 24036026]
[16]
Stabile, G.; Iuliano, A.; Agresta, A.; La Rocca, V.; D’Ascia, S.; De Simone, A. Antiarrhythmic therapy following ablation of atrial fibrillation. Expert Rev. Cardiovasc. Ther., 2013, 11(7), 837-842.
[http://dx.doi.org/10.1586/14779072.2013.811982] [PMID: 23895027]
[17]
Kim, Y.R.; Nam, G.B.; Han, S.; Kim, S.H.; Kim, K.H.; Lee, S.; Kim, J.; Choi, K.J.; Kim, Y.H. Effect of short-term steroid therapy on early recurrence during the blanking period after catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol, 2015, 8(6), 1366-1372.
[http://dx.doi.org/10.1161/CIRCEP.115.002957] [PMID: 26541350]
[18]
Koyama, T.; Tada, H.; Sekiguchi, Y.; Arimoto, T.; Yamasaki, H.; Kuroki, K.; Machino, T.; Tajiri, K.; Zhu, X.D.; Kanemoto-Igarashi, M.; Sugiyasu, A.; Kuga, K.; Nakata, Y.; Aonuma, K. Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. J. Am. Coll. Cardiol., 2010, 56(18), 1463-1472.
[http://dx.doi.org/10.1016/j.jacc.2010.04.057] [PMID: 20951321]
[19]
Won, H.; Kim, J.Y.; Shim, J.; Uhm, J.S.; Pak, H.N.; Lee, M.H. Effect of a single bolus injection of low-dose hydrocortisone for prevention of atrial fibrillation recurrence after radiofrequency catheter ablation. Circ. J., 2013, 77(1), 53-59.
[http://dx.doi.org/10.1253/circj.CJ-12-0728] [PMID: 23006726]
[20]
Kim, D.R.; Won, H.; Uhm, J.S.; Kim, J.Y.; Sung, J.H.; Pak, H.N.; Lee, M.H.; Joung, B. Comparison of two different doses of single bolus steroid injection to prevent atrial fibrillation recurrence after radiofrequency catheter ablation. Yonsei Med. J., 2015, 56(2), 324-331.
[http://dx.doi.org/10.3349/ymj.2015.56.2.324] [PMID: 25683977]
[21]
Nascimento, T.; Mota, F.; dos Santos, L.F.; de Araujo, S.; Okada, M.; Franco, M. Impact of prophylactic corticosteroids on systemic inflammation after extensive atrial ablation in pigs. Europace, 2012, 14(1), 138-145.
[http://dx.doi.org/10.1093/europace/eur259 ] [PMID: 21846643]
[22]
Andrade, J.G.; Khairy, P.; Nattel, S.; Vanella, A.; Rivard, L.; Guerra, P.G.; Dubuc, M.; Dyrda, K.; Thibault, B.; Talajic, M.; Mondesert, B.; Roy, D.; Macle, L. Corticosteroid use during pulmonary vein isolation is associated with a higher prevalence of dormant pulmonary vein conduction. Heart Rhythm, 2013, 10(10), 1569-1575.
[http://dx.doi.org/10.1016/j.hrthm.2013.07.037] [PMID: 23892341]
[23]
Dernellis, J.; Panaretou, M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J., 2004, 25(13), 1100-1107.
[http://dx.doi.org/10.1016/j.ehj.2004.04.025] [PMID: 15231367]
[24]
Liang, J.J.; Dixit, S.; Santangeli, P. Mechanisms and clinical significance of early recurrences of atrial arrhythmias after catheter ablation for atrial fibrillation. World J. Cardiol., 2016, 8(11), 638-646.
[http://dx.doi.org/10.4330/wjc.v8.i11.638] [PMID: 27957250]
[25]
Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J. Am. Coll. Cardiol., 2012, 60(18), 1790-1796.
[http://dx.doi.org/10.1016/j.jacc.2012.07.031] [PMID: 23040570]
[26]
Egami, Y.; Nishino, M.; Tanouchi, J.; Yamada, Y. Colchicine can reduce early recurrence of atrial fibrillation after pulmonary vein isolation. Circulation, 2012, 126A11249
[http://dx.doi.org/10.1161/circ.126.suppl_21.A11249 ]
[27]
Deftereos, S.; Giannopoulos, G.; Efremidis, M.; Kossyvakis, C.; Katsivas, A.; Panagopoulou, V.; Papadimitriou, C.; Karageorgiou, S.; Doudoumis, K.; Raisakis, K.; Kaoukis, A.; Alexopoulos, D.; Manolis, A.S.; Stefanadis, C.; Cleman, M.W. Colchicine for prevention of atrial fibrillation recurrence after pulmonary vein isolation: mid-term efficacy and effect on quality of life. Heart Rhythm, 2014, 11(4), 620-628.
[http://dx.doi.org/10.1016/j.hrthm.2014.02.002] [PMID: 24508207 ]
[28]
Papageorgiou, N.; Briasoulis, A.; Lazaros, G.; Imazio, M.; Tousoulis, D. Colchicine for prevention and treatment of cardiac diseases: a meta-analysis. Cardiovasc. Ther., 2017, 35(1), 10-18.
[http://dx.doi.org/10.1111/1755-5922.12226] [PMID: 27580061]
[29]
Campbell, K.B.; Cicci, T.A.; Vora, A.K.; Burgess, L.D. Beyond gout: colchicine use in the cardiovascular patient. Hosp. Pharm., 2015, 50(10), 859-867.
[http://dx.doi.org/10.1310/hpj5010-859] [PMID: 27729672]
[30]
Chruściel, P.; Sahebkar, A.; Rembek-Wieliczko, M.; Serban, M.C.; Ursoniu, S.; Mikhailidis, D.P.; Jones, S.R.; Mosteoru, S.; Blaha, M.J.; Martin, S.S.; Rysz, J.; Toth, P.P.; Lip, G.Y.; Pencina, M.J.; Ray, K.K.; Banach, M. Lipid and blood pressure meta-analysis collaboration (LBPMC) group. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, 253, 194-208.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.07.897] [PMID: 27498397]
[31]
Ferretti, G.; Bacchetti, T.; Sahebkar, A. Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res., 2015, 60, 50-73.
[http://dx.doi.org/10.1016/j.plipres.2015.08.003] [PMID: 26416579]
[32]
Katsiki, N.; Reiner, Ž.; Tedeschi Reiner, E.; Al-Rasadi, K.; Pirro, M.; Mikhailidis, D.P.; Sahebkar, A. Improvement of endothelial function by pitavastatin: a meta-analysis. Expert Opin. Pharmacother., 2018, 19(3), 279-286.
[http://dx.doi.org/10.1080/14656566.2018.1428560] [PMID: 29334477]
[33]
Mohajeri, M.; Banach, M.; Atkin, S.L.; Butler, A.E.; Ruscica, M.; Watts, G.F.; Sahebkar, A. MicroRNAs: novel molecular targets and response modulators of statin therapy. Trends Pharmacol. Sci., 2018, 39(11), 967-981.
[http://dx.doi.org/10.1016/j.tips.2018.09.005] [PMID: 30249403]
[34]
Parizadeh, S.M.R.; Azarpazhooh, M.R.; Moohebati, M.; Nematy, M.; Ghayour-Mobarhan, M.; Tavallaie, S.; Rahsepar, A.A.; Amini, M.; Sahebkar, A.; Mohammadi, M.; Ferns, G.A. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids, 2011, 46(4), 333-340.
[http://dx.doi.org/10.1007/s11745-010-3517-x] [PMID: 21207250]
[35]
Parsamanesh, N.; Moossavi, M.; Bahrami, A.; Fereidouni, M.; Barreto, G.; Sahebkar, A. NLRP3 inflammasome as a treatment target in atherosclerosis: a focus on statin therapy. Int. Immunopharmacol., 2019, 73, 146-155.
[http://dx.doi.org/10.1016/j.intimp.2019.05.006] [PMID: 31100709]
[36]
Sahebkar, A.; Kotani, K.; Serban, C.; Ursoniu, S.; Mikhailidis, D.P.; Jones, S.R.; Ray, K.K.; Blaha, M.J.; Rysz, J.; Toth, P.P.; Muntner, P.; Lip, G.Y.; Banach, M. Lipid and blood pressure meta-analysis collaboration (LBPMC) group. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis, 2015, 241(2), 433-442.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.022] [PMID: 26074317]
[37]
Sahebkar, A.; Serban, C.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Muntner, P.; Bittner, V.; Ray, K.K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.; Banach, M. Lipid and blood pressure meta-analysis collaboration (LBPMC) group. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb. Haemost., 2015, 114(3), 546-557.
[http://dx.doi.org/10.1160/th14-11-0937] [PMID: 26017749]
[38]
Sahebkar, A.; Serban, C.; Ursoniu, S.; Mikhailidis, D.P.; Undas, A.; Lip, G.Y.H.; Bittner, V.; Ray, K.; Watts, G.F.; Hovingh, G.K.; Rysz, J.; Kastelein, J.J.; Banach, M. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb. Haemost., 2016, 115(3), 520-532.
[http://dx.doi.org/10.1160/th15-08-0620] [PMID: 26632869]
[39]
Zhao, G.; Wu, L.; Liu, Y.; Gao, L.; Chen, Y.; Yao, R.; Zhang, Y. Rosuvastatin reduces the recurrence rate following catheter ablation for atrial fibrillation in patients with heart failure. Biomed. Rep., 2017, 6(3), 346-352.
[http://dx.doi.org/10.3892/br.2017.844] [PMID: 28451398]
[40]
Ozaydin, M.; Varol, E.; Aslan, S.M.; Kucuktepe, Z.; Dogan, A.; Ozturk, M.; Altinbas, A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am. J. Cardiol., 2006, 97(10), 1490-1493.
[http://dx.doi.org/10.1016/j.amjcard.2005.11.082] [PMID: 16679090]
[41]
Suleiman, M.; Koestler, C.; Lerman, A.; Lopez-Jimenez, F.; Herges, R.; Hodge, D.; Bradley, D.; Cha, Y.M.; Brady, P.A.; Munger, T.M.; Asirvatham, S.J.; Packer, D.L.; Friedman, P.A. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. Heart Rhythm, 2012, 9(2), 172-178.
[http://dx.doi.org/10.1016/j.hrthm.2011.09.016] [PMID: 21920481]
[42]
Wang, J.; Wang, A.R.; Zhang, M.J.; Li, Y. Effects of atorvastatin on serum high-sensitive c-reactive protein and total cholesterol levels in Asian patients with atrial fibrillation. Am. J. Ther., 2017, 24(1), e20-e29.
[http://dx.doi.org/10.1097/MJT.0000000000000344] [PMID: 26566148]
[43]
Yan, P.; Dong, P.; Li, Z.; Cheng, J. Statin therapy decreased the recurrence frequency of atrial fibrillation after electrical cardioversion: a meta-analysis. Med. Sci. Monit., 2014, 20, 2753-2758.
[http://dx.doi.org/10.12659/MSM.891049] [PMID: 25529758]
[44]
Wang, Z.; Zhang, Y.; Gao, M.; Wang, J.; Wang, Q.; Wang, X.; Su, L.; Hou, Y. Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Pharmacotherapy, 2011, 31(11), 1051-1062.
[http://dx.doi.org/10.1592/phco.31.11.1051] [PMID: 22026393]
[45]
Wang, C-Y.; Liu, P-Y.; Liao, J.K. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med., 2008, 14(1), 37-44.
[http://dx.doi.org/10.1016/j.molmed.2007.11.004] [PMID: 18068482]
[46]
Vizzardi, E.; Curnis, A.; Latini, M.G.; Salghetti, F.; Rocco, E.; Lupi, L.; Rovetta, R.; Quinzani, F.; Bonadei, I.; Bontempi, L.; D’Aloia, A.; Dei Cas, L. Risk factors for atrial fibrillation recurrence: a literature review. J. Cardiovasc. Med. (Hagerstown), 2014, 15(3), 235-253.
[http://dx.doi.org/10.2459/JCM.0b013e328358554b] [PMID: 23114271]
[47]
Fujita, M.; Morimoto, T.; Ikemoto, M.; Takeda, M.; Ikai, A.; Miwa, K. Dose-dependency in pleiotropic effects of atorvastatin. Int. J. Angiol., 2007, 16(3), 89-91.
[http://dx.doi.org/10.1055/s-0031-1278256] [PMID: 22477299]
[48]
Mozaffarian, D.; Psaty, B.M.; Rimm, E.B.; Lemaitre, R.N.; Burke, G.L.; Lyles, M.F.; Lefkowitz, D.; Siscovick, D.S. Fish intake and risk of incident atrial fibrillation. Circulation, 2004, 110(4), 368-373.
[http://dx.doi.org/10.1161/01.CIR.0000138154.00779.A5] [PMID: 15262826]
[49]
Kowey, P.R.; Reiffel, J.A.; Ellenbogen, K.A.; Naccarelli, G.V.; Pratt, C.M. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA, 2010, 304(21), 2363-2372.
[http://dx.doi.org/10.1001/jama.2010.1735] [PMID: 21078810]
[50]
Darghosian, L.; Free, M.; Li, J.; Gebretsadik, T.; Bian, A.; Shintani, A.; McBride, B.F.; Solus, J.; Milne, G.; Crossley, G.H.; Thompson, D.; Vidaillet, H.; Okafor, H.; Darbar, D.; Murray, K.T.; Stein, C.M. Effect of omega-three polyunsaturated fatty acids on inflammation, oxidative stress, and recurrence of atrial fibrillation. Am. J. Cardiol., 2015, 115(2), 196-201.
[http://dx.doi.org/10.1016/j.amjcard.2014.10.022] [PMID: 25465932]
[51]
Nodari, S.; Triggiani, M.; Campia, U.; Manerba, A.; Milesi, G.; Cesana, B.M.; Gheorghiade, M.; Dei Cas, L. n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion: a prospective, randomized study. Circulation, 2011, 124(10), 1100-1106.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.111.02-2194] [PMID: 21844082]
[52]
Kumar, S.; Sutherland, F.; Morton, J.B.; Lee, G.; Morgan, J.; Wong, J.; Eccleston, D.E.; Voukelatos, J.; Garg, M.L.; Sparks, P.B. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm, 2012, 9(4), 483-491.
[http://dx.doi.org/10.1016/j.hrthm.2011.11.034] [PMID: 22120130]
[53]
Bianconi, L.; Calo, L.; Mennuni, M.; Santini, L.; Morosetti, P.; Azzolini, P.; Barbato, G.; Biscione, F.; Romano, P. Massimo Santini. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace, 2011, 13(2), 174-181.
[http://dx.doi.org/10.1093/europace/euq386] [PMID: 21059740]
[54]
Ozaydin, M.; Erdogan, D.; Tayyar, S.; Uysal, B.A.; Dogan, A.; Icli, A.; Ozkan, E.; Varol, E.; Turker, Y.; Arslan, A. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study. Anadolu Kardiyol. Derg., 2011, 11(4), 305-309.
[http://dx.doi.org/10.5152/akd.2011.080] [PMID: 21543294]
[55]
Cao, H.; Wang, X.; Huang, H.; Ying, S.Z.; Gu, Y.W.; Wang, T.; Huang, C.X. Omega-3 fatty acids in the prevention of atrial fibrillation recurrences after cardioversion: a meta-analysis of randomized controlled trials. Intern. Med., 2012, 51(18), 2503-2508.
[http://dx.doi.org/10.2169/internalmedicine.51.7714] [PMID: 22989818]
[56]
Guo, X.; Dong, J.; Du, X.; Ma, C. Are omega-3 fatty acids ineffective for preventing atrial fibrillation recurrence? J. Am. Coll. Cardiol., 2013, 61(14), 1552.
[http://dx.doi.org/10.1016/j.jacc.2013.01.032] [PMID: 23500244]
[57]
Nigam, A.; Talajic, M.; Roy, D.; Nattel, S.; Lambert, J.; Nozza, A.; Jones, P.; Ramprasath, V.R.; O’Hara, G.; Kopecky, S.; Brophy, J.M.; Tardif, J.C. Fish oil for the reduction of atrial fibrillation recurrence, inflammation, and oxidative stress. J. Am. Coll. Cardiol., 2014, 64(14), 1441-1448.
[http://dx.doi.org/10.1016/j.jacc.2014.07.956] [PMID: 25277614]
[58]
Parahuleva, M.S.; Kanse, S.; Hölschermann, H.; Zheleva, K.; Zandt, D.; Worsch, M.; Parviz, B.; Güttler, N.; Tillmanns, H.; Böning, A.; Erdogan, A. Association of circulating factor seven activating protease (FSAP) and of oral Omega-3 fatty acids supplements with clinical outcome in patients with atrial fibrillation: the OMEGA-AF study. J. Thromb. Thrombolysis, 2014, 37(3), 317-325.
[http://dx.doi.org/10.1007/s11239-013-0921-0] [PMID: 23575879]
[59]
Calder, P.C. Long-chain fatty acids and inflammation. Proc. Nutr. Soc., 2012, 71(2), 284-289.
[http://dx.doi.org/10.1017/S0029665112000067] [PMID: 22369781]
[60]
Kumar, S.; Sutherland, F.; Teh, A.W.; Heck, P.M.; Lee, G.; Garg, M.L.; Sparks, P.B. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human pulmonary vein and left atrial electrophysiology in paroxysmal atrial fibrillation. Am. J. Cardiol., 2011, 108(4), 531-535.
[http://dx.doi.org/10.1016/j.amjcard.2011.03.082] [PMID: 21624541]
[61]
Kumar, S.; Sutherland, F.; Lee, J.M.; Robinson, T.; Heck, P.M.; Wong, M.C.; Kelland, N.F.; Garg, M.L.; Sparks, P.B. Effects of high dose intravenous fish oil on human atrial electrophysiology: implications for possible anti- and pro-arrhythmic mechanisms in atrial fibrillation. Int. J. Cardiol., 2013, 168(3), 2754-2760.
[http://dx.doi.org/10.1016/j.ijcard.2013.03.053] [PMID: 23602291]
[62]
Rupp, H.; Rupp, T.P.; Alter, P.; Maisch, B. Inverse shift in serum polyunsaturated and monounsaturated fatty acids is associated with adverse dilatation of the heart. Heart, 2010, 96(8), 595-598.
[http://dx.doi.org/10.1136/hrt.2009.176560] [PMID: 19723686]
[63]
Xin, W.; Wei, W.; Li, X. Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 2012, 12(1), 77.
[http://dx.doi.org/10.1186/1471-2261-12-77] [PMID: 22994912]
[64]
Glück, T.; Rupp, H.; Alter, P. Mechanisms increasing n-3 highly unsaturated fatty acids in the heart. Can. J. Physiol. Pharmacol., 2016, 94(3), 309-323.
[http://dx.doi.org/10.1139/cjpp-2015-0300] [PMID: 26780261]
[65]
Kumar, S.; Sutherland, F.; Wheeler, M.; Heck, P.M.; Lee, G.; Teh, A.W.; Garg, M.L.; Morgan, J.G.; Sparks, P.B. Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils. Heart Rhythm, 2011, 8(5), 643-649.
[http://dx.doi.org/10.1016/j.hrthm.2011.01.014] [PMID: 21232631]
[66]
He, Z.; Yang, L.; Tian, J.; Yang, K.; Wu, J.; Yao, Y. Efficacy and safety of omega-3 fatty acids for the prevention of atrial fibrillation: a meta-analysis. Can. J. Cardiol., 2013, 29(2), 196-203.
[http://dx.doi.org/10.1016/j.cjca.2012.03.019] [PMID: 22681963]
[67]
Siscovick, D.S.; Barringer, T.A.; Fretts, A.M.; Wu, J.H.; Lichtenstein, A.H.; Costello, R.B.; Kris-Etherton, P.M.; Jacobson, T.A.; Engler, M.B.; Alger, H.M.; Appel, L.J.; Mozaffarian, D. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation, 2017, 135(15), e867-e884.
[http://dx.doi.org/10.1161/CIR.0000000000000482] [PMID: 28289069]
[68]
Harada, M.; Van Wagoner, D.R.; Nattel, S. Role of inflammation in atrial fibrillation pathophysiology and management. Circ. J., 2015, 79(3), 495-502.
[http://dx.doi.org/10.1253/circj.CJ-15-0138] [PMID: 25746525]
[69]
Lazzerini, P.E.; Laghi-Pasini, F.; Acampa, M.; Srivastava, U.; Bertolozzi, I.; Giabbani, B.; Finizola, F.; Vanni, F.; Dokollari, A.; Natale, M.; Cevenini, G.; Selvi, E.; Migliacci, N.; Maccherini, M.; Boutjdir, M.; Capecchi, P.L. systemic inflammation rapidly induces reversible atrial electrical remodeling: the role of interleukin-6-mediated changes in connexin expression. J. Am. Heart Assoc., 2019, 8(16)e011006
[http://dx.doi.org/10.1161/JAHA.118.011006] [PMID: 31423933]
[70]
Korantzopoulos, P.; Kolettis, T.; Siogas, K.; Goudevenos, J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med. Sci. Monit., 2003, 9(9), RA225-RA229.
[PMID: 12960937]
[71]
Dernellis, J.; Panaretou, M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am. Heart J., 2005, 150(5), 1064.
[http://dx.doi.org/10.1016/j.ahj.2005.06.032] [PMID: 16290998]
[72]
Negi, S.; Shukrullah, I.; Veledar, E.; Bloom, H.L.; Jones, D.P.; Dudley, S.C. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J. Cardiovasc. Electrophysiol., 2011, 22(4), 414-419.
[http://dx.doi.org/10.1111/j.1540-8167.2010.01925.x] [PMID: 20946227]
[73]
Demir, K.; Can, I.; Koc, F.; Vatankulu, M.A.; Ayhan, S.; Akilli, H.; Aribas, A.; Alihanoglu, Y.; Altunkeser, B.B. Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. Med. Princ. Pract., 2011, 20(5), 464-469.
[http://dx.doi.org/10.1159/000327674] [PMID: 21757938]
[74]
Xia, W.; Yin, Z.; Li, J.; Song, Y.; Qu, X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin. Electrophysiol., 2009, 32(12), 1562-1566.
[http://dx.doi.org/10.1111/j.1540-8159.2009.02554.x] [PMID: 19793367]
[75]
Almroth, H.; Höglund, N.; Boman, K.; Englund, A.; Jensen, S.; Kjellman, B.; Tornvall, P.; Rosenqvist, M. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur. Heart J., 2009, 30(7), 827-833.
[http://dx.doi.org/10.1093/eurheartj/ehp006] [PMID: 19202157]
[76]
Yang, Q.; Qi, X.; Li, Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 2014, 14, 99.
[http://dx.doi.org/10.1186/1471-2261-14-99] [PMID: 25117689]
[77]
Fang, W.T.; Li, H.J.; Zhang, H.; Jiang, S. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Br. J. Clin. Pharmacol., 2012, 74(5), 744-756.
[http://dx.doi.org/10.1111/j.1365-2125.2012.04258.x] [PMID: 22376147]
[78]
Xu, Q.; Guan, Y.Q.; Zhang, D.; Su, G.H. The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials. Curr. Med. Res. Opin., 2011, 27(9), 1771-1779.
[http://dx.doi.org/10.1185/03007995.2011.605785] [PMID: 21806315]
[79]
Dentali, F.; Gianni, M.; Squizzato, A.; Ageno, W.; Castiglioni, L.; Maroni, L.; Hylek, E.M.; Grandi, A.M.; Cazzani, E.; Venco, A.; Guasti, L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb. Haemost., 2011, 106(2), 363-370.
[http://dx.doi.org/10.1160/th10-10-0660] [PMID: 21614408]
[80]
Bhardwaj, A.; Sood, N.A.; Kluger, J.; Coleman, C.I. Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. Int. J. Clin. Pract., 2010, 64(8), 1116-1120.
[http://dx.doi.org/10.1111/j.1742-1241.2010.02387.x] [PMID: 20642710]

Rights & Permissions Print Cite
Article Metrics
34
1
© 2024 Bentham Science Publishers | Privacy Policy